The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Switch to Biosimilar Infliximab for IBD Slashes Drug Costs

Switch to Biosimilar Infliximab for IBD Slashes Drug Costs

February 17, 2017 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK—Inflammatory bowel disease (IBD) patients can be safely switched from originator infliximab to biosimilar infliximab using a managed-switching program, U.K. research shows.

You Might Also Like
  • IBD Patients Who Switch from Infliximab to Biosimilar See Mixed Results
  • Biosimilar Infliximab Appears Safe, Effective in Pediatric IBD
  • Rheumatology Drug Updates: Infliximab Biosimilar Cross Reacts to Infliximab Antibodies

“Thus far, there does not appear to be any significant difference between the two infliximab products in terms of drug persistence, side effects, adverse reactions, disease activity, or blood tests, but ongoing follow-up is needed,” Dr. Fraser Cummings of Southampton General Hospital and colleagues write in their report, published online January 16 in the Journal of Crohn’s and Colitis.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The European Medicines Agency approved the first infliximab biosimilar, CT-P13, in 2013. There is currently little information on CT-P13 in IBD patients, especially those switched from originator infliximab, the researchers note. However, studies have shown patients with rheumatoid arthritis can be switched safely to the biosimilar drug.

In the new study, the researchers report on a managed-switching program funded through a gainsharing agreement between the University Hospital Southampton (UHS), the NHS Foundation Trust and local clinical commissioning groups (CCGs). All 143 patients at UHS who were on infliximab were offered the opportunity to switch to CT-P13, and all agreed to the switch.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

After the switching program began, drug acquisition costs fell by 40,000 pounds (about US$50,000) to 60,000 pounds (US$75,000) per month.

Investment in the new program, including salary for an IBD specialist nurse and other support staff, was about 103,000 pounds (US$129,000) per year, or about 12% of the expected cost savings. Savings were shared equally between UHS and the CCGs.

“We have demonstrated substantial cost savings to the health economy, part of which has been re-invested in not only delivering the programme but also improving the service and quality of care for the whole IBD patient population in Southampton, not just for biologics-treated patients,” Dr. Cummings and colleagues write.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Cummings was not available for an interview by press time.

Reference

  1. Razanskaite V, Bettey M, Downey L, et al. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme. J Crohns Colitis. 2017 Jan 27. pii: jjw216. [Epub ahead of print]

 

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: biosimilar, CT-P13, drug costs, IBD, infliximab, irritable bowel disease

You Might Also Like:
  • IBD Patients Who Switch from Infliximab to Biosimilar See Mixed Results
  • Biosimilar Infliximab Appears Safe, Effective in Pediatric IBD
  • Rheumatology Drug Updates: Infliximab Biosimilar Cross Reacts to Infliximab Antibodies
  • Mucosal Healing Seen with Infliximab Biosimilar CT-P13 in Ulcerative Colitis

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.